Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buprenorphine
Drug ID BADD_D00310
Description Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction.[F4715,F4718] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,F4715,F4718] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet.
Indications and Usage For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
Marketing Status Prescription; Discontinued
ATC Code N02AE01; N07BC01
DrugBank ID DB00921
KEGG ID D07132
MeSH ID D002047
PubChem ID 644073
TTD Drug ID D06AWE
NDC Product Code 51927-0062; 12578-607; 65724-0050; 0093-3659; 71335-0353; 42858-586; 60687-492; 62756-460; 59011-750; 65267-203; 67509-003; 12496-0100; 60687-481; 42858-353; 69238-1203; 42858-501; 59011-758; 62756-459; 71335-1154; 12496-0300; 69238-1505; 38779-3255; 59011-751; 68071-2592; 59011-757; 50090-5805; 73548-1039; 0093-3657; 0792-0631; 59011-752; 71335-0950; 69238-1202; 69238-1204; 0228-3153; 42858-502; 49812-0239; 0093-3239; 70518-1625; 42858-750; 0093-3658; 42858-493; 42858-839; 71795-2200; 0093-3656; 10920-593; 0228-3156; 12707-036; 47848-030; 69238-1205
Synonyms Buprenorphine | Buprenex | Prefin | Subutex | Buprex | Temgesic | Temgésic | 6029-M | 6029 M | 6029M | RX-6029-M | RX 6029 M | RX6029M | Buprenorphine Hydrochloride | Hydrochloride, Buprenorphine
Chemical Information
Molecular Formula C29H41NO4
CAS Registry Number 52485-79-7
SMILES CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Throat irritation22.02.05.013; 07.05.03.0040.001859%Not Available
Throat tightness19.01.02.005; 22.02.05.0150.001859%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.006505%
Tooth disorder07.09.05.0010.001859%Not Available
Toothache07.09.06.0010.001859%
Torsade de pointes02.03.04.0050.001859%Not Available
Tremor17.01.06.0020.032524%
Trigeminal neuralgia17.04.08.0010.001859%Not Available
Ulcer08.03.06.0010.002788%Not Available
Unresponsive to stimuli17.02.05.0310.005576%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary hesitation20.02.02.0090.003717%Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.0110.006505%
Urinary tract infection11.01.14.004; 20.08.02.001--
Urinary tract malformation20.08.03.002; 03.06.02.0030.001859%Not Available
Urticaria23.04.02.001; 10.01.06.0010.023232%
Uterine disorder21.07.01.0060.001859%Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Viral upper respiratory tract infection11.05.04.007; 22.07.02.0040.001859%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.0030.077130%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Withdrawal syndrome19.07.02.005; 08.06.02.0120.011151%Not Available
Wrist fracture15.08.03.007; 12.04.01.0080.001859%
Yawning22.02.05.0170.002788%Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages